PCI术后残余炎症风险与临床结局的关联
38%的患者存在持续高残余炎症风险(hsCRP≥2 mg/L),其1年全因死亡率和心肌梗死发生率均显著高于其他组,校正糖尿病、急性冠脉综合征及基线LDL后结果仍持续。
要点
- PCI术后38%患者存在持续高残余炎症风险(hsCRP≥2 mg/L)。
- 持续高RIR患者1年全因死亡率2.6%、心梗7.5%,均显著高于其他组。
- PCI术后应识别残余炎症风险,并进一步探索治疗选项。
核心结论
- PCI术后持续高残余炎症风险常见,且与1年全因死亡率和心肌梗死率显著升高相关。
- 校正糖尿病、急性冠脉综合征和基线低密度脂蛋白后,结果仍持续。
研究设计与样本
- 回顾性队列研究,数据来自大型前瞻性单中心PCI注册,纳入2009至2016年接受PCI且有连续炎症状态评估的患者。
主要发现
- 持续高RIR 2654例(38%),RIR升高719例(10%),RIR减弱1088例(15%),持续低RIR 2565例(37%)。
- 1年全因死亡率:持续高RIR 2.6%,RIR升高1.0%,RIR减弱0.3%,持续低RIR 0.7%,P<0.01。
- 1年心肌梗死率:持续高RIR 7.5%,RIR升高6.4%,RIR减弱4.6%,持续低RIR 4.3%,P<0.01。
关键数值与推荐
- 高残余炎症风险定义为hsCRP≥2 mg/L。
- 分组依据基线与随访hsCRP:持续高、先低后高(升高)、先高后低(减弱)、持续低。
- 主要终点为1年随访全因死亡率,心肌梗死为次要结局。
临床怎么用
- 对PCI术后患者可考虑连续监测hsCRP以识别持续高残余炎症风险者。
- 持续高RIR患者1年死亡和心梗风险较高,提示需关注并进一步探索治疗选项。
局限性
- 为单中心回顾性队列研究。
- 仅30.8%的PCI患者有连续hsCRP检测,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: It remains unknown what percentage of patients treated with percutaneous coronary artery intervention (PCI) have high residual inflammatory risk (RIR). Moreover, the impact of RIR on clinical outcomes has not been established. The objective of this study is to determine the prevalence of patients with persistent high levels of inflammation after PCI and to evaluate clinical outcomes according to inflammatory response. METHODS AND RESULTS: This is a retrospective cohort study assessing patients undergoing PCI between 2009 and 2016 with serial inflammatory status assessment from a large, prospective, and single-centre PCI registry. Assessment of inflammation status with at least two high sensitive C-reactive protein (hsCRP) measurements at baseline and follow-up with >4 weeks apart. High RIR was defined as an hsCRP≥ 2 mg/L. Patients were divided into four groups: persistent high RIR, increased RIR (first low-, then high hsCRP), attenuated RIR (first high-, then low hsCRP), or persistent low RIR. The primary endpoint was all-cause mortality at 1 year follow-up. Occurrence of myocardial infarction (MI) was assessed as secondary outcome. Seven thousand and twenty-six patients were identified with serial hsCRP measurements (30.8% of all PCI patients). Of these patients 2654 (38%) had persistent high RIR, 719 patients (10%) had increased RIR, 1088 patients (15%) had attenuated RIR, and persistent low RIR was seen in 2565 patients (37%). All-cause mortality at 1 year was 2.6% in patients with persistent high RIR, compared with 1.0% in increased RIR, 0.3% in attenuated RIR, and 0.7% in persistent low RIR patients, P < 0.01. MI at 1 year was observed in 7.5% of persistent high RIR, compared with 6.4% in increased RIR, 4.6% in attenuated RIR, and 4.3% in persistent low RIR, P < 0.01. In an adjusted model, including accounting for diabetes mellitus, acute coronary syndrome, and baseline low-density lipoprotein, results were sustained. CONCLUSION: Persistent high RIR is observed frequently in patients undergoing PCI. In these patients, significantly higher all-cause mortality and MI rates are observed at 1 year follow-up. Residual inflammatory risk in patients undergoing PCI should be identified and treatment options should be further explored.
引用
- Kalkman DN, Aquino M, Claessen BE, et al. Residual inflammatory risk and the impact on clinical outcomes in patients after percutaneous coronary interventions. Eur Heart J. 2018. PMID: 30358832. doi:10.1093/eurheartj/ehy633
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。